Skip to content

13F-HR filed by Caligan Partners LP

Caligan Partners LP filed this 13F-HR for the quarter ended 2026-06-30, filed 2026-08-14, with 28 holding rows worth $2,125,706,950.

Accession
0001420506-26-001809
Filed
2026-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2026

A holdings report, 28 entries on the cover page, a total value of $2,125,706,950 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,125,706,950 with VALUE read as dollars as filed, 13F file number 028-23096. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
LIQUIDIA CORPORATION COM NEW53635D202Stock8,118,892$647,319,259dollars as filed
REVOLUTION MEDICINES INC COM76155X100Stock1,961,795$367,404,968dollars as filed
ABIVAX SA-00370M103SPONSORED ADS1,557,924$207,608,952dollars as filed
VAXCYTE INC COM92243G108Stock2,188,636$127,225,411dollars as filed
EXELIXIS INC COM30161Q104Stock1,553,262$84,512,985dollars as filed
TANGO THERAPEUTICS INC87583X109COM2,500,103$78,153,220dollars as filed
AVALO THERAPEUTICS INC05338F306COMMON STOCK3,163,866$58,468,244dollars as filed
XENON PHARMACEUTICALS INC COM98420N105Stock889,944$53,717,020dollars as filed
ADMA BIOLOGICS INC000899104COM5,725,007$47,918,309dollars as filed
REVOLUTION MEDICINES INC COM76155X100Stock251,800$47,157,104dollars as filedcall
LB PHARMACEUTICALS INC50180M108COMMON STOCK1,438,070$46,672,562dollars as filed
IMMUNOCORE HLDGS PLC ADS45258D105ADR1,381,317$43,856,815dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM2,193,981$40,303,431dollars as filed
VOR BIOPHARMA INC929033207COMMON STOCK1,925,066$35,440,465dollars as filed
SAB BIOTHERAPEUTICS INC78397T202COMMON STOCK7,967,207$31,072,107dollars as filed
INVENTIVA SA46124U107ADS8,163,191$30,856,862dollars as filed
AURA BIOSCIENCES INC05153U107COMMON STOCK4,298,248$30,517,561dollars as filed
TYRA BIOSCIENCES INC90240B106COMMON STOCK806,986$25,775,133dollars as filed
OPUS GENETICS INC67577R102COMMON STOCK6,077,084$24,976,815dollars as filed
ANIKA THERAPEUTICS INC035255108COM1,435,130$20,995,952dollars as filed
SAGIMET BIOSCIENCES INC A786700104COMMON STOCK2,500,000$19,325,000dollars as filed
ARTIVA BIOTHERAPEUTICS INC04317A107COM1,736,111$16,840,277dollars as filed
FAETH THERAPEUTICS INC81728A207COM NEW629,467$15,736,675dollars as filed
MBX BIOSCIENCES INC COM55287L101Stock200,000$11,040,000dollars as filed
VERRICA PHARMACEUTICALS INC92511W207COM SHS923,910$5,654,329dollars as filed
AGIOS PHARMACEUTICALS INC00847X104COM90,000$3,339,900dollars as filedcall
ADMA BIOLOGICS INC000899104COM300,000$2,511,000dollars as filedcall
CELLECTAR BIOSCIENCES INC15117F880COM NEW469,998$1,306,594dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001420506-26-001809this filing2026-08-14acceptance time not in the bulk data set